康希諾生物(06185.HK)澄清稱與加拿大國家研究委員會的合作並未終止
格隆匯8月27日丨康希諾生物(06185.HK)公告,公司注意到部分媒體有關重組新型冠狀病毒疫苗(腺病毒載體)加拿大臨牀試驗的誤導性報導。
為免對公司股東及潛在投資者產生誤導,公司謹此作出以下澄清及聲明:截至本公告發布之日,加拿大國家研究委員會與公司的合作並未終止。於最近一段時間內,公司管理層均未接受任何與Ad5-nCoV在加拿大臨牀試驗相關的採訪;及公司目前正在與多個國家共同推動Ad5-nCoV的國際多中心III期臨牀試驗。
除本公告所披露者外,經就公司作出一切合理查詢後,公司董事會確認其並無知悉根據香港法例第571章證券及期貨條例第XIVA部項下內幕消息條文及香港聯合交易所有限公司證券上市規則第13.09條須披露的任何內幕消息。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.